Ferinject ® (Ferric carboxymaltose)

DRUG2 trials

Sponsors

Vifor Pharma

Conditions

AnaemiaChronic Heart FailureIron DeficiencyIron Deficiency Anemia

Phase 3

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

CompletedNCT00520780

Vifor PharmaAnaemia, Chronic Heart Failure, Iron Deficiency +1

Start: 2007-04-30End: 2009-09-30Updated: 2021-10-14

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

TerminatedNCT00821717

Vifor PharmaAnaemia, Chronic Heart Failure, Iron Deficiency +1

Start: 2008-12-31End: 2011-01-31Updated: 2015-06-03

Related Papers

Ferric carboxymaltose in patients with heart failure and iron deficiency.

2009-11-171386 citations

Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.

2009-11-0182 citations